Cancer Education Blog

By J. Christopher Paschold, MD, FACP

Virginia Oncology Associates (VOA) was recently selected as one of only ten sites in the country to be part of a collaborative that includes McKesson and life science companies participating in a clinical research study called MYLUNG. MYLUNG is a lung cancer clinical trial that stands for Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium. The work of this consortium, which will eventually involve more than 12,000 patients, is to better understand metastatic non-small cell lung cancer at the molecular level and develop more targeted treatment plans.

Cancer does not discriminate. Whether these malignancies are caused by genetics, environmental exposure or simply bad luck, the road to recovery is harrowing and unfortunately, not always guaranteed. Men are particularly susceptible to a handful of cancers that carry a history of high death tolls. Today’s oncologists are working to change that as they break ground on new treatments and immunotherapies that surpass the success of traditional cytotoxic chemotherapy. “What’s being developed are treatments that target certain molecular structures either in or on the cancer cell,” says Dr. Thomas Alberico of Virginia Oncology Associates. “Where before we were seeing response rates in the five to 10 percent range with standard chemotherapy, now we’re seeing response rates in the 40, 50 and 60 percent range [with new therapies].”

You probably know tobacco use is bad for your health. In fact, over-the-counter tobacco products are legally required to include one of the following warning labels reminding the public of tobacco’s dangers, especially the dangers of cancer.

By: Graham T. Watson, MD – Virginia Oncology Associates

The quickly expanding knowledge of cancer biology has led to new, highly effective treatments for patients with non-small cell lung cancer (NSCLC). Advances in genetics have brought about targeted therapy with drugs that “target” a specific driver mutation. With a deeper understanding of the immune system’s interaction with cancer cells, we can uncloak cancer cells that previously hid from immune destruction. For years, we have leveraged these therapies only in Stage IV lung cancer, but cancer research has shown that Stage III patients treated first with chemoradiotherapy can also gain benefit.

Advances in Immunotherapy Treatment Options for Lung Cancer

 Immunotherapies such as nivolumab (Opdivo®) or pembrolizumab (Keytruda®) have helped patients with incurable, Stage IV lung cancer live longer. While these drugs represent a major breakthrough, limiting their use to Stage IV patients is a frustration for both patients and doctors. While the goal of treatment in Stage III lung cancer patients is cure, the rates of recurrence are high. Finding a lung cancer treatment that can reduce this risk of recurrence is a worthy goal.

What is the American Cancer Society's Great American Smokeout? It's an annual event, held the third Thursday of every November, a date on which smokers nationwide are asked to give up smoking. Quitting for just one day helps you take action toward a healthier life, and reduce your lung cancer risk.

Each year, the Great American Smokeout calls attention to the deaths, lung cancer diagnoses, and other chronic diseases that smoking causes, and how to prevent them. As a result of this event, there have been actions taken towards reducing the health impacts that smoking can have on smokers and non-smokers including: